Real time. No replacement. No lag.
GluTronics measures light, not enzymes. Zero consumables. Zero ISF delay. Clinical accuracy parity — in a permanent, wearable optical architecture.
Every 14 days, the sensor becomes a cost center.
Enzymatic sensors depend on biochemical inference — which introduces 5–15 minutes of ISF lag and mandates perpetual sensor replacement. The consumable model is not a feature. It is a built-in margin ceiling.
GluTronics uses a skin-tone agnostic optical-first approach: light through tissue, direct physiological signal, zero-replacement architecture. The ISF lag problem is structurally eliminated — not mitigated.
Clinical proof. Enterprise-grade IP fortress.
Clinical accuracy parity — validated.
IP fortress with full FTO clearance.
Validation studies confirm MARD performance within FDA-grade CGM accuracy benchmarks. Skin-tone agnostic across the full Fitzpatrick scale. Enterprise-ready, not prototype-stage.
A defensible patent portfolio covering optical wavelength selection, tissue-scattering algorithms, and wearable integration. Freedom-to-operate confirmed. First-party integration is legally clean.
The acquisition case is already built.
Full acquisition, OEM licensing, and co-development structures are defined and ready for diligence. Request the partnership brief to begin.